TORONTO, Dec. 29, 2016 /CNW/ - Brent Zettl, President and CEO, CanniMed Therapeutics Inc. (TSX:CMED) joined Brady Fletcher, Managing Director, TSX Venture Exchange to open the market. CanniMed is a Canadian-based, international plant biopharmaceutical company with 15 years of pharmaceutical cannabis cultivation experience. The Company has a plant biotechnology research and product development program focused on the production of plant-based materials for pharmaceutical, agricultural and environmental applications. CanniMedTherapeutics Inc., will commence trading on Toronto Stock Exchange on December 29, 2016.

SOURCE TMX Group Limited